MANAGED CARE October 1997. ©1997 Stezzi Communications

COLLECTIONS WRITTEN TEST ANSWERS

For each of the following circle "True" or "False":

1. A patient who is not satisfied with treatment does not have to pay.

        False

2. If the divorce decree states that the father is
responsible for medical bills, you may not pursue the mother if she brings the child in for treatment.

        False

3. You may not call a patient after 8 p.m.

        False

4. You must accept a $5 payment from a patient no matter how large the bill is.

        False

5. If you are a participating provider for an HMO or PPO, there is nothing you can do if you are not happy with the plan's determination of payment.

        False

6. You may not call patients at work.

        False

7. Checks that are postdated are illegal.

        True

8. You must wait at least 30 days before turning past-due accounts over to collection.

        False

9. You may not turn a patient's account over for collection without first informing him.

        False

10. You may not charge insurance companies for additional information.

        False

11. If the insurance company says you are charging more than is "usual and customary," there is nothing you can do.

        False

12. You may not charge interest on medical bills.

        False

13. The only person you may speak to regarding the debt is the patient.

        False

14. If a patient owes you money, you may withhold transferring medical records until he pays you.

        False

15. You may not run credit checks on your patients without their permission.

        True

16. It's illegal to sue on a medical debt.

        False

Back to the article "Written Tests Can Help You Hire the Best Employees"

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.